Year-end Sale % OFF 
Abstract
This study was conducted to test the efficacy and toxicity of cetuximab and irinotecan as a biweekly regimen in treatment of elderly patients with metastatic colorectal cancer (mCRC). Forty-nine elderly patients (≥65years) with mCRC who progressed after at least one previous line of treatment were enrolled into this study from May 2008 to January 2011. All recruited patients received cetuximab 500mg/m(2) and irinotecan 180mg/m(2) every 2weeks. Thirty-seven patients (76%) were men, and 76% of patients had colonic cancer in origin. Median age was 69years. Median overall survival time was 7months, and median progression-free survival was 4months. Grade 3-4 skin rash occurred in 20% of patients, grade 3-4 diarrhea in 18% of patients, and neutropenia in 28% of patients. Cetuximab combined with irinotecan when administered biweekly is safe and effective for treatment of pretreated elderly patients with mCRC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
